Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Classification of MSH6 Variants of Uncertain Significance Using Functional Assays

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Gastrin and the moderate hypergastrinemias

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. HDL cholesterol and non-cardiovascular disease: a narrative review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. The Role of Leptin in Fetal Growth during Pre-Eclampsia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Using machine learning for predicting intensive care unit resource use during the COVID-19 pandemic in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth. TNFi exposure may alter the immune system of the infant towards hypersensitivity and reduced response to intracellular infections. Confounding by indication should be considered, as chronic inflammatory disease itself may pose a risk of adverse pregnancy outcomes. The quality of the current evidence is very low and no studies specifically address TNFi safety in women with psoriasis. Nonetheless, risks associated with TNFi treatment must be balanced against the as-yet uncertain risk of adverse outcomes in infants born to women with severe psoriasis. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. Herein, we present the current knowledge of the use and safety of TNFi during pregnancy in women with psoriasis.

OriginalsprogEngelsk
TidsskriftInternational Journal of Molecular Sciences
Vol/bind19
Udgave nummer5
ISSN1661-6596
DOI
StatusUdgivet - 3 maj 2018

ID: 55741536